Cargando…

Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma

BACKGROUND: Immune checkpoint inhibitor (ICI)-combined chemotherapy in advanced intrahepatic cholangiocarcinoma has been proved to have more efficacy in a series of clinical trials. However, whether the tumor microenvironment (TME) plays a vital role in immune-combined therapy has not been rigorousl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Tian-mei, Pan, Yu-fei, Yuan, Zhen-gang, Chen, Dong-sheng, Song, Yun-jie, Gao, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501891/ https://www.ncbi.nlm.nih.gov/pubmed/36159865 http://dx.doi.org/10.3389/fimmu.2022.943066

Ejemplares similares

PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature
por: Wang, Zhihong, et al.
Publicado: (2021)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma
por: Zhang, Zhuochao, et al.
Publicado: (2023)

Lenvatinib Combined With a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma
por: Xie, Lulu, et al.
Publicado: (2022)

Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report
por: Zhang, Ze, et al.
Publicado: (2021)

PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review
por: Liao, Chun-Xu, et al.
Publicado: (2023)

Inflammation-Based Scores Predict Responses to PD-1 Inhibitor Treatment in Intrahepatic Cholangiocarcinoma
por: Yang, Zhenyun, et al.
Publicado: (2022)

Immune-related adverse events correlate with the efficacy of PD-1 inhibitors combination therapy in advanced cholangiocarcinoma patients: A retrospective cohort study
por: Zhang, Yanfang, et al.
Publicado: (2023)

Case Report: Camrelizumab combined with gemcitabine and oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma: a case report and literature review
por: Zhang, Zhongyan, et al.
Publicado: (2023)

Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis
por: Yang, Xue-Gang, et al.
Publicado: (2022)

Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review
por: Zhang, Wei, et al.
Publicado: (2023)

PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
por: Fontugne, Jacqueline, et al.
Publicado: (2017)

M2 macrophage inhibits the antitumor effects of Lenvatinib on intrahepatic cholangiocarcinoma
por: Yang, Long, et al.
Publicado: (2023)

Clinicopathological and Prognostic Significance of Immunoscore and PD-L1 in Intrahepatic Cholangiocarcinoma
por: Wu, Hong, et al.
Publicado: (2021)

Case report: Conversion therapy for advanced intrahepatic cholangiocarcinoma using PD-1 inhibitor plus S-1 and nab-paclitaxel
por: Li, Xiaocheng, et al.
Publicado: (2022)

Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma
por: Huang, Jia-Xin, et al.
Publicado: (2023)

Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
por: Wu, Tianyu, et al.
Publicado: (2021)

Identification of a novel microRNA signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis
por: Zhang, Mei-Yin, et al.
Publicado: (2015)

Identification of immune related gene signature for predicting prognosis of cholangiocarcinoma patients
por: Zhang, Zi-jian, et al.
Publicado: (2023)

PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome
por: Tian, Lingyu, et al.
Publicado: (2020)

CD86(+)/CD206(+) tumor-associated macrophages predict prognosis of patients with intrahepatic cholangiocarcinoma
por: Sun, Dalong, et al.
Publicado: (2020)

Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy
por: Zhang, Xi, et al.
Publicado: (2022)

A Myeloid Signature-Based Nomogram Predicts the Postoperative Recurrence of Intrahepatic Cholangiocarcinoma
por: Liang, Jing, et al.
Publicado: (2021)

Genomic and Immune Features in an Intrahepatic Cholangiocarcinoma Patient with Microsatellite Instability-High Suffered Rapid Acquired Resistance to PD-1 Inhibitor
por: Cheng, Zhuo, et al.
Publicado: (2023)

Intrahepatic Sarcomatoid Cholangiocarcinoma
por: Malhotra, Shalini, et al.
Publicado: (2010)

Asbestos and Intrahepatic Cholangiocarcinoma
por: Brandi, Giovanni, et al.
Publicado: (2020)

Management of Intrahepatic Cholangiocarcinoma
por: Kodali, Sudha, et al.
Publicado: (2021)

Successful treatment of stage IIIB intrahepatic cholangiocarcinoma using neoadjuvant therapy with the PD-1 inhibitor camrelizumab: A case report
por: Zhu, Shu-Guang, et al.
Publicado: (2022)

Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors
por: Lu, Jia-Cheng, et al.
Publicado: (2019)

Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma
por: Chen, Xing, et al.
Publicado: (2022)

Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma
por: Chun, Yun Shin, et al.
Publicado: (2017)

Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: A Case Report
por: Liu, Ze-Long, et al.
Publicado: (2020)

TP53 /KRAS Co-Mutations Create Divergent Prognosis Signatures in Intrahepatic Cholangiocarcinoma
por: Guo, Chunguang, et al.
Publicado: (2022)

Percutaneous microwave ablation combined with simultaneous transarterial chemoembolization for the treatment of advanced intrahepatic cholangiocarcinoma
por: Yang, Guo-Wei, et al.
Publicado: (2015)

Dissecting Intra-Tumoral Changes Following Immune Checkpoint Blockades in Intrahepatic Cholangiocarcinoma via Single-Cell Analysis
por: Sun, Bao-Ye, et al.
Publicado: (2022)

Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis
por: Xian, Feng, et al.
Publicado: (2023)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Patients' prognosis of intrahepatic cholangiocarcinoma and combined hepatocellular‐cholangiocarcinoma after resection
por: Song, Peipei, et al.
Publicado: (2019)

Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma
por: Auer, Timo Alexander, et al.
Publicado: (2023)

A metabolism-related 4-lncRNA prognostic signature and corresponding mechanisms in intrahepatic cholangiocarcinoma
por: Zou, Wenbo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e0bu34lf7n5gtbdadj6oll5n9s